The U.S. Food and Drug Administration Gives the Green Light to Molecure’s Flagship Program – Phase II Clinical Testing of OATD-01 Is Ready for Launch

Molecure S.A. has received of its Investigational New Drug (IND) Application from the US FDA. This IND will allow the company to conduct phase II clinical testing of OATD-01, the first-ever chitotriosidase 1 inhibitor with disease-modifying potential. The first pulmonary sarcoidosis patients in this Phase II study are scheduled to begin receiving treatment in Q4 2O23.